In the Press

Pipetting Samples

FZATA RECENT GRANTS

2021

7/22/2021 Fzata WINS NIH PHASE 2 SBIR GRANT 

Grant will support development of, "A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridium difficile Infection". This will be a diagnostic ELISA to assist physicians in selecting appropriate treatment for patients at risk of C. Diff infection.


5/1/2021 Fzata WINS NIH SBIR FAST TRACK GRANT ON IBD NOVEL IMMUNOTHERAPY

Fzata is awarded a NIH SBIR Fast track grant on our very first IBD project, a novel oral yeast immunotherapies for Ulcerative Colitis.

3/30/2021 Fzata WINS NIH SBIR FAST-TRACK GRANT

Fzata wins NIH SBIR Fast-track grant to support the development of FZ002.

2man taking FZata capsule.png

Fzata Announces First-in-Class “Live Biologics In A Pill” Platform Entering Manufacturing Phase

08/11/2021

Fzata, Inc. is developing our ground-breaking “Live Biologics In A Pill” platform for oral delivery of live biologics. Live Biologics In A Pill will open up a new route of oral administration for innovative live biologic therapeutics. Fzata is pleased to announce that our lead drug, FZ002, has advanced to manufacturing stage and IND-enabling studies. FZ002 is a first-in-class live biotherapeutic product (LBP) yeast for the treatment of Clostridioides difficile (C. diff) infection.  C. diff bacteria can cause life-threatening diarrhea. Infections occur most often in people who have taken antibiotics for other conditions. It is the most common healthcare-associated infection and the CDC has labeled it at the highest urgent threat level. Click for Full Article

FullSizeRender 4.jpg

FZ002 R&D is published in top journal

10/28/2020

Research on Fzata's leading drug candidate, FZ002, was published in
Science Translational Medicine (2020 Oct 28;12(567)).
This break through study was reported by many journals, including Science magazine (https://www.sciencemag.org/news/2020/10/antibody-producing-yeast-vanquishes-deadly-gut-infection-mice), Medical Press (https://medicalxpress.com/news/2020-10-yeast-common-bacterial-intestinal-infection.html), BiotechScope (https://biotechscope.com/antibody-secreting-yeast-immunotherapy-to-treat-deadly-gut-infection/) etc.

IMG_6419.JPG



Fzata is spotlighted by EAGB

March 1, 2020

EAGB selected Fzata as their Industry Spotlight: Life Science company. 
(https://www.greaterbaltimore.org/news/blog/thriving-against-odds-life-sciences-industry)

FullSizeRender 26.jpg





Fzata, Inc. Wins 3rd SBIR Fund

01/20/2018

Fzata is awarded an SBIR grant to support the development of a novel companion diagnostic assay for C. diff infection

FullSizeRender%208_edited.jpg





Fzata Wins 2nd SBIR fund

01/15/2018

Fzata receives an SBIR Phase I grant to support the development of a novel immunotherapy against comorbidity of C. diff infection and Inflammatory Bowel Disease

FullSizeRender 11.jpg






Fzata Wins  NIH R01 Grant

March 1, 2017

Fzata is awarded an NIH R01 grant to support the development of a novel multi- specific antibody against C. diff infection.

trophy.jpeg





Fzata is honored "2017 Maryland Incubator Company of the Year: Best Life Science Company"

06/15/2017

It's our great honor to be selected as the Maryland best life science incubator company! Saul Ewing, the Maryland Technology Development Corporation (TEDCO) and McGladrey established the Maryland Incubator Company of the Year Awards in 2001.

(https://technical.ly/baltimore/2017/06/16/maryland-incubator-company-2017/)

(https://news.umbc.edu/2017-maryland-incubator-company-of-the-year-awards-recognize-three-bwtechumbc-startups/)

Screen%20Shot%202021-04-08%20at%2010.43_edited.jpg





Fzata, Inc. Wins Its First SBIR Grant

01/01/2017

Fzata is awarded a SBIR Phase I grant from NIAID to support the study of a novel oral immuo-therapy against C. diff infection.

​As NIH grant awardee, Fzata will strictly follow the NIH policy on Financial Conflict of Interest.